Cyberonics reneged on its "Lifetime Reimbursement Guarantee". Click on the image to learn how you can help...
Showing posts with label Deep Brain. Show all posts
Showing posts with label Deep Brain. Show all posts

Thursday, July 18, 2013

Real-time adaptive brain control: Combining a BCI with DBS to treat Parkinson’s

Real-time adaptive brain control: Combining a BCI with DBS to treat Parkinson’s

Adaptive DBS

Share This article

0
inShare

We have been following the advances in deep brain stimulation (DBS) pretty closely here at ET. Just the other week, we explained the motivations behind treatments for Parkinson’s disease with DBS electrodes placed in the subthalamic nucleus, and hinted at a couple of ways that they might be improved. Perhaps the biggest advance in DBS systems since they were first developed has just been reported by a group of researchers working in the Movement Disorders Group at Oxford University. By recording activity with what is essentially a brain-computer interface (BCI), the researchers were able to close the stimulation loop with direct feedback from the subthalamic nucleus. The ability to incorporate meaningful data from the implant user’s brain into the moment-to-moment control of the stimulation puts the one-size-fits-all DBS system on the fast track to obsolescence — and ushers in the new era of personalized implants.

Once activated, most DBS systems generate continuous pulses, typically at a frequency above 100Hz. Always-on stimulation fatigues not only the batteries, but more importantly the brain itself. The symptoms of Parkinson’s disease fluctuate continuously and any form of smart control needs to be fast to be effective. Previous research has demonstrated that the spike output of motor neurons in the cortex of a monkey could be used as feedback to provide better results than continuous stimulation. Directly implementing these results in humans calls for a bit more caution though — blunt exploratory implantation of multiple brain areas comes at a price. The Oxford group, led by Peter Brown, realized that the stimulation electrodes themselves can be used to record local field potentials. These signals are not the signatures of single cells, but can be thought of instead as more diffuse summary reports of larger groups of cells.

Monkey DBS

In order to use these averaged potentials for control, some criteria is needed to pass judgement on their desirability. Studies in Parkinson’s patients have consistently shown that subthalamic nucleus activity in the beta frequency band (3-30Hz) correlates with motor impairment. Brown’s group was able to build a control system that was able to filter and capture activity in this band, and then use it to control the stimulation current. The device was tested in eight patients and provided significant improvements over both continuous and random stimulation conditions.

This proof-of-principle demonstration provides a tantalizing glimpse of what lies ahead. For now, the control hardware is a bulky external system, although work on miniaturizing its footprint to fit inside the skull is ongoing. Once that happens, we have the essentials of two closely-related kinds of devices that are also under development in several labs. One is a device to police undesirable activity, like for example, seizures. In fact an important study in this area just appeared in the journal Neurosurgery. The other, more intriguing use is for what is commonly referred to as a “memory implant.”

DBS Electrode

DBS electrodes, reaching down into a human’s brain

There is really no substantial, convincing, evidence yet that memory implants are practical. The main problem is that we don’t know how to interpret what little brain activity we can manage to record. What I suspect we will find going forward is that, rather than attempting to build memory implants from scratch that access high-level areas of the brain (like the hippocampus), they will instead directly evolve from the on-board learning algorithms, and storage, that are built into motor control implants like those described here.

The pace of advance of these kinds of implants will be driven to a large degree by the pace at which they are made open. Interoperability between components is essential, as well as keeping the user in the loop to provide direct input to device designers. A huge boost in this area was just provided by Medtronic, the leading implant manufacturer, when it finally caved to overwhelming user demand for access to critical data generated by their implants. The irony of users having better feedback from an inexpensive Fitbit than from their $30,000 implant was not lost on vocal advocate, user, and TED Talk giver, Hugo Campos. Others were quick to jump on Medtronic CEO, Omar Ischrak when he tweeted how much he enjoyed access to his Runtastic data, yet at the same time denying feedback to users of his own products.

Opening implant data to users is harmless enough, although giving them unbridled control over critical parameters certainly has its risks. The larger community has already realized what the medical community has been slow to accept — the benefits of providing users with control over their implants far outweighs these risks, and that fact can no longer be ignored. Increasingly, we interact with our external environment through our personal electronic devices — that same power, and ease of interaction, for our inner space will be sought, demanded, and granted.

Now read: An ultrasonic intra-body communication network for bionic implants

Paper: DOI: 10.1002/ana.23951 – “Adaptive deep brain stimulation in advanced Parkinson disease” [Free PDF]

http://www.extremetech.com/extreme/161411-real-time-adaptive-brain-control-combining-a-bci-with-dbs-to-treat-parkinsons

Monday, March 25, 2013

Research and Markets Announces The Release of 'Neuromodulation Market - Forecasts to 2017'

 
PR Newswire  
 
 
 
 

 
 

Research and Markets Announces The Release of 'Neuromodulation Market - Forecasts to 2017'

DUBLIN, March 25, 2013 /PRNewswire/ --
 
Research and Markets (http://www.researchandmarkets.com/research/t8zp6f/neuromodulation) has announced the addition of the "Neuromodulation Market - [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] - Forecasts to 2017" report to their offering.
 
Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non-invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS).
 
The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder.
 
The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer's, epilepsy, spinal cord injury, and Parkinson's disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. The large pool of patients that suffer from depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor offers the neuromodulation industry opportunities to grow in the next five years. The market for treatment of tinnitus, in particular, represents an emerging application of neuromodulation. According to the American Tinnitus Association, about 50 million people currently (2012) suffer from this disease in the U.S.
 
Key Topics Covered:
1 INTRODUCTION
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
4 GLOBAL NEUROMODULATION MARKET (INTERNAL & EXTERNAL)
5 GEOGRAPHIC ANALYSIS
6 COMPETITIVE LANDSCAPE
7 COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*
Companies Mentioned
- Anm Adaptive Neuromodulation Gmbh
- Biocontrol Medical, Ltd.
- Boston Scientific Corporation
- Cerbomed Gmbh
- Cyberonics, Inc.
- Endostim, Inc.
- Enteromedics, Inc.
- The Magstim Company Limited
- Medtronic, Inc.
- Neuronetics, Inc.
- Neuropace, Inc.
- Neurosigma, Inc.
- Nevro Corporation
- Rs Medical
- Spinal Modulation, Inc.
- St. Jude Medical
- Synapse Biomedical, Inc.
- Uroplasty, Inc.
- Zynex, Inc.
 
Research and Markets

Laura Wood , Senior Manager
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Medical Devices

SOURCE Research and Markets

 
 
Links referenced within this article

http://www.researchandmarkets.com/research/t8zp6f/neuromodulationhttp://www.researchandmarkets.com/research/t8zp6f/neuromodulation
http://photos.prnewswire.com/prnh/20130307/600769http://photos.prnewswire.com/prnh/20130307/600769
http://www.researchandmarkets.com/research/t8zp6f/neuromodulationhttp://www.researchandmarkets.com/research/t8zp6f/neuromodulation
press@researchandmarkets.comhttp://www.prnewswire.com/news-releases/mailto:press@researchandmarkets.com